论文信息 - After 6 years with Xolair; a 3‐year withdrawal follow‐up - 字舞流文

After 6 years with Xolair; a 3‐year withdrawal follow‐up

Background: This study reports the clinical and immunological state of patients 3 years after a 6‐year period of Xolair treatment for severe allergic asthma.

M. Palmqvist | S. Johansson | J. Ankerst | A. Nopp | J. Adédoyin | H. Öman

[1] L. Cardell,et al. The size of the disease relevant IgE antibody fraction in relation to ‘total‐IgE’ predicts the efficacy of anti‐IgE (Xolair®) treatment , 2009, Allergy.

[2] L. Cardell,et al. CD‐sens: a biological measure of immunological changes stimulated by ASIT , 2009, Allergy.

[3] M. Palmqvist,et al. CD‐sens and clinical changes during withdrawal of Xolair after 6 years of treatment , 2007, Allergy.

[4] M. Palmqvist,et al. Basophil allergen threshold sensitivity: a useful approach to anti‐IgE treatment efficacy evaluation , 2006, Allergy.

[5] L. Söderström,et al. Passive IgE‐sensitization by blood transfusion , 2005, Allergy.

[6] R. Fick,et al. IgE and Anti-IgE Therapy in Asthma and Allergic Disease , 2002 .

[7] T. Casale,et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. , 2001, JAMA.

[8] A. Togias,et al. Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo , 1999, The Journal of Immunology.

[9] A. Togias,et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.